All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
Following the 2021 ASCO Annual Meeting and the EHA 2021 Virtual Congress, the Lymphoma Hub spoke with John C. Byrd, OSUCCC −The James, Columbus, US. We asked, Is acalabrutinib superior to ibrutinib for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)?
Is acalabrutinib superior to ibrutinib for the treatment of R/R CLL?
Byrd outlines data from the phase III ELEVATE-RR trial, a non-inferiority study which was the first to compare safety and overall survival between the BTK inhibitors acalabrutinib and ibrutinib, in patients with previously treated CLL.
Impact of novel treatment options on long-term outcomes in CLL and WM
William Wierda, MD Anderson Cancer Center, Houston, US, discusses the impact of novel treatment options on long-term outcomes in chronic lymphocytic leukemia (CLL).
What novel targeted therapies are currently under investigation for R/R CLL?
During the 2021 ASCO Annual Meeting, the Lymphoma Hub spoke with Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What novel targeted therapies are...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox